Lupin has acquired the anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim to bolster its diabetes portfolio in India. The transfer will be complete by March next year. Lupin has been co-marketing these drugs since 2016 and 2018, respectively. This acquisition strengthens Lupin's commitment to providing affordable diabetes medications.
